Investigational drug · Phase 2
Danvatirsen
Also called: AZD9150
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
14
Any phase or sponsor naming "Danvatirsen"
First trial start
2017
Dec 18, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Danvatirsen", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Danvatirsen" as an intervention, largest first.
- Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03334617 · 528 participants · Start Dec 18, 2017 · Primary completion Sep 13, 2024
Drug: Durvalumab; Danvatirsen and 6 more · For: Non-Small Cell Lung Cancer
Sites: Duarte, California; Fullerton, California; La Jolla, California · 45 sites in all
- Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & NeckPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT02499328 · 340 participants · Start Aug 6, 2015 · Primary completion Feb 28, 2020
Drug: AZD9150; MEDI4736 and 2 more · For: Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Sites: Birmingham, Alabama; Duarte, California; La Jolla, California · 44 sites in all
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03819465 · 175 participants · Start Dec 27, 2018 · Primary completion May 23, 2023
Drug: Durvalumab; Danvatirsen and 8 more · For: Metastatic Non-Small Cell Lung Cancer (NSCLC)
Sites: Iowa City, Iowa; Pittsburgh, Pennsylvania; Nashville, Tennessee · 41 sites in all
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT02546661 · 117 participants · Start Dec 28, 2016 · Primary completion Mar 18, 2020
Drug: AZD4547; MEDI4736 and 5 more · For: Muscle Invasive Bladder Cancer
Sites: Los Angeles, California; New Haven, Connecticut; Fort Myers, Florida · 27 sites in all
MedImmune LLCAstraZeneca (AZN)
NCT03794544 · 84 participants · Start Mar 8, 2019 · Primary completion Jan 13, 2021
Drug: Durvalumab · For: Resectable; Early-stage; NSCLC
Sites: La Jolla, California; Fort Myers, Florida; Leesburg, Florida · 18 sites in all
AstraZenecaAstraZeneca (AZN)
NCT03421353 · 76 participants · Start Feb 7, 2018 · Primary completion Jan 17, 2020
Drug: AZD9150; Durvalumab and 5 more · For: Advanced Solid Tumours
Sites: Lafayette, Indiana; Oklahoma City, Oklahoma; Nashville, Tennessee · 6 sites in all
Flamingo Therapeutics NVIndustry
NCT05814666 · 69 participants · Start May 30, 2023 · Primary completion Aug 14, 2025
Drug: Danvatirsen; Pembrolizumab · For: HNSCC
Sites: Tucson, Arizona; Irvine, California; Torrance, California · 32 sites in all
AstraZenecaAstraZeneca (AZN)
NCT01839604 · 58 participants · Start May 2013 · Primary completion Feb 2015
Drug: AZD9150 · For: Advanced Adult Hepatocellular Carcinoma; Hepatocellular Carcinoma Metastatic
Sites: Hong Kong, Hong Kong; Chūōku, Japan; Kashiwa-shi, Japan · 7 sites in all
- Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal CancerActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT02983578 · 39 participants · Start Mar 2, 2017 · Primary completion Aug 30, 2025
Drug: Danvatirsen; Durvalumab · For: Advanced Colorectal Carcinoma; Advanced Lung Non-Small Cell Carcinoma; Lung Non-Small Cell Carcinoma and 22 more
Sites: Houston, Texas
- Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AMLRecruiting
Montefiore Medical CenterAcademic, hospital or other
NCT05986240 · 38 participants (planned) · Start May 8, 2024 · Primary completion Jun 2027
Drug: Danvatirsen · For: AML/MDS; Acute Myeloid Leukemia; Myelodysplastic Syndromes
Sites: The Bronx, New York; Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Danvatirsen plus Pembrolizumab versus Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma (PEMDA-HN): A Randomized, Phase II Trial.
Saba NF, Posner M, Harrington KJ, et al. · Clin Cancer Res 2026
- Oligonucleotide-Based Modulation of Macrophage Polarization: Emerging Strategies in Immunotherapy.
Zhang H, Yu Y, Qian C · Immun Inflamm Dis 2025
- STAT3 Signaling Pathway in Health and Disease.
Samad MA, Ahmad I, Hasan A, et al. · MedComm (2020) 2025
- Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.
Tang C, Hartley GP, Couillault C, et al. · BMJ Oncol 2024
- Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
Besse B, Pons-Tostivint E, Park K, et al. · Nat Med 2024
- Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
Cascone T, Kar G, Spicer JD, et al. · Cancer Discov 2023
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AstraZeneca.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.